The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...

The frontrunner at the moment is Vertex Pharma, whose NaV1.8 inhibitor suzetrigine (formerly VX-548) has already been filed for approval in the US for two moderate-to-severe acute pain indications ...

Small-capitalization stocks posted positive returns for the quarter, but they lagged their large-cap counterparts.